A few clinically active, yet expensive, options such as acetylcholinesterase inhibitors, interferon β-1a, levodopa, tetrabenazine, and tissue type plasminogen activator (tPA) are available for AD [42], MS [43], PD [44], HD [45], and stroke [46], respectively. This evidence concerns the gene ACHE and Alzheimer disease.